600276 恒瑞医药
已收盘 09-03 15:00:00
资讯
新帖
简况
恒瑞医药(600276.SH)：奥特康唑胶囊获得药品注册批准
智通财经 · 09-03 17:07
恒瑞医药(600276.SH)：奥特康唑胶囊获得药品注册批准
恒瑞医药市值蒸发近500亿：员工持股目标下调，离职补偿累计近3亿
财中社 · 09-03 14:29
恒瑞医药市值蒸发近500亿：员工持股目标下调，离职补偿累计近3亿
恒瑞医药(01276)：HRS-7535片的药品上市许可申请获国家药监局受理
智通财经 · 09-02 18:19
恒瑞医药(01276)：HRS-7535片的药品上市许可申请获国家药监局受理
恒瑞医药(01276)截至8月末尚未开始实施A股股份回购
智通财经 · 09-02 17:14
恒瑞医药(01276)截至8月末尚未开始实施A股股份回购
恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参
每日经济新闻 · 09-01 09:23
恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参
【高端访谈】“自主研发+协同创新”双轮驱动 公司迈入新发展阶段—访先声药业周云曙
新华财经 · 08-31
【高端访谈】“自主研发+协同创新”双轮驱动 公司迈入新发展阶段—访先声药业周云曙
恒瑞医药中报遇冷：老明星药渐入暮年 营收四年首现半年度负增长
新浪证券 · 08-27
恒瑞医药中报遇冷：老明星药渐入暮年 营收四年首现半年度负增长
恒瑞医药获GIC Private Limited增持384.38万股 每股作价约48.15港元
新浪港股 · 08-27
恒瑞医药获GIC Private Limited增持384.38万股 每股作价约48.15港元
摩根大通在江苏恒瑞医药H股的空头头寸于8月21日攀升至3.72%，此前为2.57%——港交所披露
美股速递 · 08-26
摩根大通在江苏恒瑞医药H股的空头头寸于8月21日攀升至3.72%，此前为2.57%——港交所披露
GIC Private Limited增持恒瑞医药(01276)365.86万股 每股作价约50.57港元
智通财经网 · 08-25
GIC Private Limited增持恒瑞医药(01276)365.86万股 每股作价约50.57港元
恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理
智通财经 · 08-24
恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理
恒瑞医药半年报解读：高投入难换高增长 昔日“医药一哥”增收难增利
市场资讯 · 08-24
恒瑞医药半年报解读：高投入难换高增长 昔日“医药一哥”增收难增利
【券商聚焦】交银国际维持恒瑞医药（01276）中性评级 指存量品种或持续承压
金吾财讯 · 08-24
【券商聚焦】交银国际维持恒瑞医药（01276）中性评级 指存量品种或持续承压
恒瑞医药（01276）增长结构生变：第二曲线提速 全球价值释放
智通财经 · 08-23
恒瑞医药（01276）增长结构生变：第二曲线提速 全球价值释放
先声药业核心管理层再次调整 周云曙不再担任CEO
南方财经网 · 08-21
先声药业核心管理层再次调整 周云曙不再担任CEO
恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市
美股速递 · 08-20
恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市
恒瑞医药(01276) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验
智通财经 · 08-20
恒瑞医药(01276) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验
恒瑞医药富马酸立康可泮胶囊获药品注册批准
北京商报 · 08-20
恒瑞医药富马酸立康可泮胶囊获药品注册批准
恒瑞医药：子公司3款药物获批临床
财中社 · 08-20
恒瑞医药：子公司3款药物获批临床
恒瑞医药：HRS-3095片获临床试验批准
南方财经网 · 08-20
恒瑞医药：HRS-3095片获临床试验批准
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.96,"timestamp":1788418800000,"preClose":45.57,"halted":0,"volume":50291740,"delay":0,"changeRate":0.0086,"floatShares":6379000000,"shares":6637000000,"eps":1.1642,"marketStatus":"已收盘","change":0.39,"latestTime":"09-03 15:00:00","open":45.6,"high":46.09,"low":45.36,"amount":2300000000,"amplitude":0.016,"askPrice":45.96,"askSize":336,"bidPrice":45.95,"bidSize":1181,"shortable":0,"etf":0,"ttmEps":1.1642,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":45.57,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":50.13,"lowLimit":41.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.73,"roa":"--","peRate":39.477753,"roe":"8.04%","epsLYR":1.19,"committee":0.20421,"marketValue":305046000000,"turnoverRate":0.0079,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":46.16,"timestamp":1788422901002,"preClose":45.5,"halted":0,"volume":4334000,"delay":0,"premium":"-13.95"},"floatMarketCap":293179000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2664357878","title":"恒瑞医药(600276.SH)：奥特康唑胶囊获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664357878","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664357878?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:07","pubTimestamp":1788426473,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局的通知，批准公司奥特康唑胶囊境内生产药品注册上市。奥特康唑用于治疗复发性外阴阴道假丝酵母菌病的适应症已于2022年在美国获批上市，被公司引进后于2023年获批上市，用于治疗VVC。经查询，奥特康唑同类产品2025年全球销售额合计约22.30亿美元。截至目前，奥特康唑胶囊相关项目累计研发投入约2.19亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1820825898.SGD","LU2148510915.USD","LU1997244956.HKD","LU1655091616.SGD","600276","BK0012","LU2097828631.EUR","LU2488822045.USD","LU2097828714.EUR","BK0060","LU0405327148.USD","LU2543165471.USD","LU1580142542.USD","BK0183","LU2097828805.USD","LU2580892789.USD","LU1023057109.AUD","LU1997245177.USD","01276","BK0239","LU0359201612.USD","LU1997245094.SGD","LU0359202008.SGD","LU1969619763.USD","LU1064130708.USD","BK0188","LU1781817850.SGD","BK1191","BK0196","LU1146622755.USD","LU1255011170.USD","LU0405327494.USD","LU2097828557.USD","BK0028","LU0359201885.HKD","LU2097828474.EUR","LU2495084118.USD","LU1064131003.USD","LU2328871848.SGD","LU2289578879.USD","LU1328615791.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664821024","title":"恒瑞医药市值蒸发近500亿：员工持股目标下调，离职补偿累计近3亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2664821024","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664821024?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:29","pubTimestamp":1788416940,"startTime":"0","endTime":"0","summary":"日前，恒瑞医药（600276）披露2026年半年度报告，营收下滑、扣非净利润承压，业绩表现不及市场预期。半年报披露的隔日即8月20日，公司股价应声下跌，A股收盘报49.5元，单日下跌6%；港股单日跌幅达9.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033863987440.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033863987440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","LU2580892862.HKD","LU2097828631.EUR","BK0188","LU1781817850.SGD","LU0359201885.HKD","LU1997245177.USD","01276","LU1969619763.USD","LU1023057109.AUD","BK0183","BK0196","LU1997245094.SGD","LU2148510915.USD","LU2488822045.USD","LU0359202008.SGD","LU1655091616.SGD","BK0028","LU1064130708.USD","LU0405327494.USD","BK0239","LU2097828557.USD","LU0359201612.USD","LU2097828805.USD","600276","LU1255011170.USD","LU1328615791.USD","LU1997244956.HKD","LU2289578879.USD","BK1191","LU0405327148.USD","LU2543165471.USD","LU1146622755.USD","BK0060","LU2328871848.SGD","LU2097828714.EUR","LU2580892789.USD","BK0012","LU1820825898.SGD","LU2495084118.USD","LU1580142542.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881354","title":"恒瑞医药(01276)：HRS-7535片的药品上市许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881354","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881354?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:19","pubTimestamp":1788344348,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司山东盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司HRS-7535片的药品上市许可申请获国家药监局受理。两项研究分别针对在单纯饮食和运动血糖控制不佳的T2DM患者及经二甲双胍治疗后血糖控制不佳的T2DM患者，评价HRS-7535片的有效性和安全性。截至目前，HRS-7535片相关项目累计研发投入约49,440万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","BK0183","BK0060","LU1580142542.USD","LU1997245094.SGD","BK1191","LU2580892789.USD","LU2097828474.EUR","LU2148510915.USD","LU1064130708.USD","LU1146622755.USD","LU1255011170.USD","LU0359201612.USD","BK0012","LU2328871848.SGD","LU0405327148.USD","BK0196","BK0188","LU2097828631.EUR","LU1997244956.HKD","LU1781817850.SGD","LU0359202008.SGD","LU2580892862.HKD","LU2097828557.USD","LU2495084118.USD","IPOS","LU2097828714.EUR","BK0239","BK0028","LU1820825898.SGD","600276","LU1064131003.USD","LU2289578879.USD","01276","LU1328615791.USD","LU0405327494.USD","LU2488822045.USD","LU1655091616.SGD","LU1969619763.USD","LU0359201885.HKD","LU2097828805.USD","LU1023057109.AUD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897043","title":"恒瑞医药(01276)截至8月末尚未开始实施A股股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897043","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897043?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:14","pubTimestamp":1788340475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至2026年8月31日，公司尚未开始实施股份回购。截至本公告披露日，本次回购实施情况与回购股份方案不存在差异。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2289578879.USD","LU1023057109.AUD","LU2580892862.HKD","600276","LU1255011170.USD","03188","159982","BK0196","83130","BK0028","LU0359202008.SGD","LU0359201885.HKD","02827","LU2097828557.USD","LU1064130708.USD","LU2495084118.USD","LU0405327494.USD","LU1064131003.USD","LU2097828805.USD","LU2543165471.USD","07233","BK0012","LU1580142542.USD","82846","01276","BK0183","LU2097828474.EUR","BK0060","LU1997244956.HKD","LU1328615791.USD","BK1147","BK1191","LU1655091616.SGD","LU1969619763.USD","LU1997245177.USD","399300","LU0405327148.USD","LU2097828714.EUR","LU2097828631.EUR","LU1146622755.USD","83188","BK0188","LU2488822045.USD","BK0239","02846","03130","LU0359201612.USD","LU1781817850.SGD","LU1820825898.SGD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664884462","title":"恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2664884462","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664884462?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:23","pubTimestamp":1788225791,"startTime":"0","endTime":"0","summary":"截至8月31日收盘，三大指数集体收涨，医药板块集体调整。医药ETF（512120）跟踪指数下跌1.46%，生物医药ETF（159508）跟踪指数下跌1.4%，港股通生物科技ETF（159102）跟踪指数下跌3.61%。相关个股中，泰格医药上涨5.9%，云南白药上涨0.78%，沃森生物下跌4.83%，长春高新下跌3.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860997079.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860997079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","159938","01276","LU1997245094.SGD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU2097828474.EUR","BK0183","BK1191","LU1255011170.USD","BK1574","LU2097828631.EUR","LU1969619763.USD","LU2097828805.USD","LU1328615791.USD","LU0405327494.USD","BK0188","LU2543165471.USD","LU1064131003.USD","BK0012","600276","LU2580892862.HKD","LU2289578879.USD","LU1146622755.USD","LU2495084118.USD","LU1023057109.AUD","LU1997244956.HKD","LU2097828714.EUR","BK1161","LU1655091616.SGD","LU1820825898.SGD","BK0239","BK0196","LU0359202008.SGD","BK1515","LU1064130708.USD","09939","LU0359201612.USD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU1580142542.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663027666","title":"【高端访谈】“自主研发+协同创新”双轮驱动 公司迈入新发展阶段—访先声药业周云曙","url":"https://stock-news.laohu8.com/highlight/detail?id=2663027666","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663027666?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:19","pubTimestamp":1788157149,"startTime":"0","endTime":"0","summary":"新华财经南京8月31日电（记者朱程）2026年上半年，先声药业交出了一份亮眼成绩单：总营收45.8亿元，同比增长27.8%；经调整净利润9.6亿元，同比增长48.7%；创新药收入占比攀升至85%。这份业绩如何取得？先声药业的国际化布局有哪些新部署？AI制药未来会如何改变行业？近日，记者带着这些问题专访了先声药业集团总裁周云曙。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860023942.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860023942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828805.USD","LU2580892789.USD","BK0239","LU1580142542.USD","LU2097828557.USD","LU1781817850.SGD","LU1969619763.USD","LU1820825898.SGD","LU1997245177.USD","BK0012","LU1064130708.USD","LU2097828474.EUR","LU2580892862.HKD","LU1997245094.SGD","LU1064131003.USD","LU2488822045.USD","LU2495084118.USD","BK1191","BK0196","LU1255011170.USD","LU2097828631.EUR","LU1328615791.USD","BK1583","LU1997244956.HKD","LU1655091616.SGD","02096","LU0405327494.USD","LU1146622755.USD","BK0060","600276","BK0028","LU0405327148.USD","LU2289578879.USD","LU2148510915.USD","LU2328871848.SGD","BK0188","BK0183","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662642771","title":"恒瑞医药中报遇冷：老明星药渐入暮年 营收四年首现半年度负增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662642771","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662642771?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:16","pubTimestamp":1787818560,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药披露2026年半年度报告。营收四年首现半年度负增长扣非与现金流大幅走弱从财务数据看，恒瑞医药2026年上半年交出的成绩单难言乐观。营业收入154.56亿元，同比下降1.94%，这是公司自2023年以来首次出现半年度营收负增长。2026年上半年，恒瑞医药创新药销售收入88.09亿元，同比增长16.38%，占药品销售收入比重突破六成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-08-27/doc-iniptxkt5352108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662396725","title":"恒瑞医药获GIC Private Limited增持384.38万股 每股作价约48.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662396725","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662396725?lang=zh_cn&edition=full","pubTime":"2026-08-27 08:09","pubTimestamp":1787789340,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，8月21日，GIC Private Limited增持恒瑞医药（01276）384.38万股，每股作价48.1522港元，总金额约为1.85亿港元。增持后最新持股数目为4439.34万股，持股比例为17.19%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-08-27/doc-inipthnz5506434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GIC","BK0028","01276","LU1997245094.SGD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU2097828474.EUR","BK0183","BK1191","LU1255011170.USD","LU2097828631.EUR","LU1969619763.USD","LU2097828805.USD","LU1328615791.USD","LU0405327494.USD","BK0188","LU2543165471.USD","LU1064131003.USD","BK0012","600276","LU2580892862.HKD","LU2289578879.USD","LU1146622755.USD","LU2495084118.USD","LU1023057109.AUD","LU1997244956.HKD","LU2097828714.EUR","LU1655091616.SGD","LU1820825898.SGD","BK0239","BK0196","LU0359202008.SGD","LU1064130708.USD","BK4104","EWH","LU0359201612.USD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU1580142542.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157155193","title":"摩根大通在江苏恒瑞医药H股的空头头寸于8月21日攀升至3.72%，此前为2.57%——港交所披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157155193","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157155193?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:29","pubTimestamp":1787740156,"startTime":"0","endTime":"0","summary":"据香港交易所披露，摩根大通在江苏恒瑞医药股份有限公司H股的空头持仓比例发生显著变动。数据表明，截至8月21日，该机构的空头头寸已从先前记录的2.57%大幅上调至3.72%。\n此番调整，无疑彰显了摩根大通对于恒瑞医药H股后市走势的看空立场有所强化。市场观察人士指出，此类空头仓位的增加，往往伴随着投资者对标的股票短期表现持谨慎态度。\n港交所的定期披露机制，为市场参与者提供了观察大型金融机构持仓动向的透明窗口。摩根大通此番操作的细节，已成为业界关注的焦点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU2580892789.USD","BK0239","LU1580142542.USD","LU2097828557.USD","LU1781817850.SGD","01276","LU1969619763.USD","LU1820825898.SGD","LU1997245177.USD","BK0012","LU1023057109.AUD","LU1064130708.USD","LU2097828474.EUR","LU2580892862.HKD","LU1997245094.SGD","LU1064131003.USD","LU2488822045.USD","LU2495084118.USD","BK1191","BK0196","LU1255011170.USD","LU2097828631.EUR","LU1328615791.USD","LU1997244956.HKD","LU1655091616.SGD","LU0359201885.HKD","LU0359202008.SGD","LU0405327494.USD","LU1146622755.USD","BK0060","LU2543165471.USD","600276","BK0028","LU0405327148.USD","LU2289578879.USD","LU2148510915.USD","LU2328871848.SGD","BK0188","BK0183","LU2097828714.EUR","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773976","title":"GIC Private Limited增持恒瑞医药(01276)365.86万股 每股作价约50.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773976","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773976?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:20","pubTimestamp":1787656834,"startTime":"0","endTime":"0","summary":"8月20日，GIC Private Limited增持恒瑞医药(01276)365.86万股，每股作价50.5655港元，总金额约为1.85亿港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260825/20260825192029_32311.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260825/20260825192029_32311.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600276","BK0188","LU0359201612.USD","BK0028","LU1023057109.AUD","LU1064131003.USD","LU1580142542.USD","LU2097828714.EUR","LU0405327494.USD","LU1781817850.SGD","LU2328871848.SGD","LU2488822045.USD","01276","LU2580892862.HKD","LU2580892789.USD","BK0183","LU1997244956.HKD","LU0405327148.USD","LU1969619763.USD","BK0012","LU0359201885.HKD","LU2097828557.USD","LU1255011170.USD","BK0239","LU1146622755.USD","LU2495084118.USD","BK0060","BK1191","LU2097828474.EUR","LU1820825898.SGD","LU2097828631.EUR","GIC","LU2148510915.USD","LU1997245094.SGD","LU2097828805.USD","LU1328615791.USD","LU0359202008.SGD","LU2289578879.USD","BK0196","EWH","LU1064130708.USD","BK4104","LU1655091616.SGD","LU1997245177.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661043274","title":"恒瑞医药(01276)：HRG2010胶囊的药品上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2661043274","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661043274?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:20","pubTimestamp":1787581248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司收到国家药品监督管理局下发的《受理通知书》，公司HRG2010胶囊的药品上市许可申请获国家药监局受理。HRG2010 胶囊是公司自主研发的2类新药，为左旋多巴与外周脱羧酶抑制剂卡比多巴组成的复方制剂，通过优化释放机制，以期实现起效迅速、药效持久且平稳。经查询EvaluatePharma数据库，以上同类产品2025年全球销售额合计约为3.28亿美元。截至目前，HRG2010胶囊相关项目累计研发投入约8420万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2289578879.USD","LU1023057109.AUD","LU2580892862.HKD","LU2328871848.SGD","600276","LU1255011170.USD","BK0196","BK0028","LU0359202008.SGD","LU0359201885.HKD","LU2097828557.USD","LU1064130708.USD","LU2495084118.USD","LU0405327494.USD","LU1064131003.USD","LU1997245094.SGD","LU2097828805.USD","LU2543165471.USD","BK0012","LU1580142542.USD","01276","BK0183","LU2097828474.EUR","BK0060","LU1997244956.HKD","LU1328615791.USD","LU2148510915.USD","BK1191","LU1655091616.SGD","LU1969619763.USD","LU1997245177.USD","LU0405327148.USD","LU2097828714.EUR","LU2097828631.EUR","LU1146622755.USD","IPOS","BK0188","LU2488822045.USD","BK0239","LU0359201612.USD","LU1781817850.SGD","LU1820825898.SGD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293262","title":"恒瑞医药半年报解读：高投入难换高增长 昔日“医药一哥”增收难增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293262","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661293262?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:17","pubTimestamp":1787555820,"startTime":"0","endTime":"0","summary":"2026年8月，恒瑞医药正式对外披露半年报，这份被市场寄予厚望的中期成绩单，未能延续行业对“创新药龙头复苏高增长”的预期。上半年总营收154.56亿元，同比2025年同期157.61亿元下滑1.9%，出现阶段性半年度营收负增长。证监会黑龙江监管局处罚文书显示，恒瑞医药前董事长周云曙在职期间，利用行业合作内幕信息交易司太立股票，违法获利45万元，监管部门2025年9月作出处罚，没收全部违法所得并处50万元罚款。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-24/doc-inipkzxr0043463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","01276","LU2097828714.EUR","BK0239","LU1064131003.USD","LU0359202008.SGD","LU2495084118.USD","LU0405327494.USD","LU1655091616.SGD","LU2580892862.HKD","BK1515","BK0060","09939","LU1820825898.SGD","BK0012","LU2328871848.SGD","LU2289578879.USD","LU1580142542.USD","LU2148510915.USD","LU1255011170.USD","LU1328615791.USD","LU1997245094.SGD","BK1161","LU1969619763.USD","LU1781817850.SGD","LU2543165471.USD","BK0196","LU0359201612.USD","BK1191","LU1023057109.AUD","LU1064130708.USD","BK1574","LU0405327148.USD","LU2488822045.USD","LU1146622755.USD","LU1997245177.USD","LU2580892789.USD","600276","LU2097828474.EUR","LU2097828631.EUR","159938","LU2097828557.USD","BK0188","BK0183","LU1997244956.HKD","LU2097828805.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661242707","title":"【券商聚焦】交银国际维持恒瑞医药（01276）中性评级 指存量品种或持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2661242707","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661242707?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:17","pubTimestamp":1787537823,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，恒瑞医药 1H26收入同比下降2%至154.6亿元，其中产品销售增长2%。创新药收入同比+16%，占药品总销售额比重升至63%，其中非肿瘤创新药销售收入同比+74%，肿瘤创新药增长2.6%，增速放缓主因成熟品种竞争加剧或竞品集采降价带来压力。仿制药收入同比下滑16%，主要受存量大品种地方集采的影响。扣非归母净利润同比-12.7%至37.3亿元。该机构下调DCF目标价至57港元/54.6元人民币，后续潜在升幅有限，当前估值合理，维持中性评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989114","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","600276","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661243816","title":"恒瑞医药（01276）增长结构生变：第二曲线提速 全球价值释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2661243816","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661243816?lang=zh_cn&edition=full","pubTime":"2026-08-23 20:58","pubTimestamp":1787489920,"startTime":"0","endTime":"0","summary":"8月19日，恒瑞医药交出了一份韧性十足的半年报成绩单。更值得关注的是，恒瑞的增长结构正在发生变化。上半年，公司非肿瘤创新药销售收入达25.45亿元，同比增长73.97%，占创新药销售收入的比重进一步提升至28.89%。上半年恒瑞医药研发投入46.05亿元，同比增长18.96%，占营收比重达29.8%。长期以来，市场对恒瑞医药的认知高度锚定于抗肿瘤领域。“NewCo”模式则构成全球价值释放的第二条路径。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1255011170.USD","LU0359201612.USD","LU2580892789.USD","LU2097828631.EUR","BK0183","LU2289578879.USD","600276","LU2580892862.HKD","LU0405327148.USD","BK0060","BK0028","LU0405327494.USD","LU1146622755.USD","LU1997245177.USD","LU2097828474.EUR","LU1328615791.USD","LU0359201885.HKD","LU1997245094.SGD","BK0012","LU2148510915.USD","BK0188","BK0196","LU1655091616.SGD","LU2328871848.SGD","LU2488822045.USD","BK1191","LU2097828557.USD","LU2097828714.EUR","LU1820825898.SGD","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU1023057109.AUD","LU1064130708.USD","LU1969619763.USD","LU1781817850.SGD","LU2543165471.USD","LU0359202008.SGD","LU1997244956.HKD","01276","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661810255","title":"先声药业核心管理层再次调整 周云曙不再担任CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2661810255","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661810255?lang=zh_cn&edition=full","pubTime":"2026-08-21 08:52","pubTimestamp":1787273520,"startTime":"0","endTime":"0","summary":"【先声药业核心管理层再次调整 周云曙不再担任CEO】先声药业集团有限公司（02096.HK）在发布2026年中期业绩的同时宣布：为进一步加快中国业务发展以及加强全球创新能力建设，经周云曙博士建议及董事会批准，任晋生先生将担任首席执行官并继续担任董事长及执行董事，周博士将担任本公司总裁，自2026年8月20日起生效。公告特别提到，周云曙没有离开先声，仍将深度参与集团经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213848527126.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213848527126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","LU2580892862.HKD","LU2328871848.SGD","600276","LU1255011170.USD","BK0196","BK0028","LU2097828557.USD","LU1064130708.USD","LU2495084118.USD","LU0405327494.USD","LU1064131003.USD","LU1997245094.SGD","BK0012","LU1580142542.USD","BK0183","LU2097828474.EUR","BK0060","BK1583","LU1997244956.HKD","02096","LU1328615791.USD","LU2148510915.USD","BK1191","LU1655091616.SGD","LU1969619763.USD","LU1997245177.USD","LU0405327148.USD","LU2097828714.EUR","LU2097828631.EUR","LU1146622755.USD","BK0188","LU2488822045.USD","BK0239","LU2097828805.USD","LU1781817850.SGD","LU1820825898.SGD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143598499","title":"恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1143598499","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143598499?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:35","pubTimestamp":1787222114,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其自主研发的1类创新药利康帕泛富马酸胶囊已正式获得国家药品监督管理局批准，准许上市销售。这一里程碑式的进展，标志着公司在创新药研发领域再度取得重大突破。据悉，该药物作为全新一代治疗产品，其获批上市有望为相关疾病患者提供全新的治疗选择。值得注意的是，利康帕泛富马酸胶囊从临床前研究到最终获批，历经了严格的科学验证与审评流程，其安全性、有效性及质量可控性均获得了监管部门的充分认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU2580892862.HKD","BK1191","LU2097828805.USD","LU1064131003.USD","LU2097828557.USD","LU0359201885.HKD","BK0239","LU2488822045.USD","LU1255011170.USD","LU2097828631.EUR","BK0060","LU1328615791.USD","LU1580142542.USD","LU1655091616.SGD","BK0012","LU1146622755.USD","BK0196","LU1820825898.SGD","LU2580892789.USD","LU2289578879.USD","LU1997245177.USD","LU0359201612.USD","LU0359202008.SGD","LU1997245094.SGD","LU2097828474.EUR","LU2495084118.USD","LU1023057109.AUD","BK0183","600276","BK0028","LU2328871848.SGD","LU2097828714.EUR","01276","LU1997244956.HKD","LU2148510915.USD","LU1969619763.USD","LU0405327494.USD","LU0405327148.USD","BK0188","LU1781817850.SGD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660837902","title":"恒瑞医药(01276) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660837902","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660837902?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:22","pubTimestamp":1787221372,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于 SHR-7012 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-7012 注射液是公司自主研发的创新型药物，拟用于治疗皮肤型红斑狼疮。经查询，国内外目前暂无同靶点药物获批上市。截至目前，SHR-7012 注射液相关项目累计研发投入约 2,550 万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","LU2097828714.EUR","LU1328615791.USD","LU1820825898.SGD","LU1997245094.SGD","BK1191","LU2148510915.USD","LU2495084118.USD","BK0012","LU2097828805.USD","IBBQ","BK0196","LU1655091616.SGD","LU1997244956.HKD","LU1997245177.USD","PSYK","BK0188","LU0359201885.HKD","LU1023057109.AUD","LU2580892789.USD","MDTX","LU2543165471.USD","LU2097828474.EUR","LU1255011170.USD","BK0060","BK0239","LU0405327494.USD","LU1146622755.USD","LU2097828557.USD","LU1969619763.USD","LU0405327148.USD","LU2488822045.USD","BMED","LU2097828631.EUR","LU1781817850.SGD","LU1064130708.USD","BK0183","IBBJ","LU0359202008.SGD","LU1064131003.USD","LU0359201612.USD","LU1580142542.USD","LU2289578879.USD","BK0028","LU2328871848.SGD","600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660283161","title":"恒瑞医药富马酸立康可泮胶囊获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660283161","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660283161?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:59","pubTimestamp":1787219960,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药发布公告称，公司子公司成都盛迪医药有限公司近日收到国家药品监督管理局的通知，批准公司自主研发的1类新药富马酸立康可泮（HRS-5965）胶囊上市。根据公告，富马酸立康可泮胶囊是一种补体因子B抑制剂，作为靶向补体旁路途径的近端补体抑制，其通过抑制旁路途径的异常激活与补体扩增循环，从机制层面同时抑制血管内溶血和血管外溶血，提升血红蛋白水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847895762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847895762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","LU1969619763.USD","LU2488822045.USD","BK0012","BK0196","LU1023057109.AUD","LU2097828474.EUR","BK1191","LU2543165471.USD","LU1064131003.USD","LU1655091616.SGD","LU2580892789.USD","LU1580142542.USD","LU2097828805.USD","LU2097828714.EUR","LU2148510915.USD","LU0405327494.USD","LU1781817850.SGD","LU0359202008.SGD","BK0028","LU1146622755.USD","LU2097828631.EUR","LU2328871848.SGD","01276","LU1997245177.USD","LU1820825898.SGD","LU0359201885.HKD","LU1997244956.HKD","LU2097828557.USD","BK0188","BK0239","BK0060","LU1255011170.USD","LU1328615791.USD","BK0183","LU1064130708.USD","LU0359201612.USD","600276","LU1997245094.SGD","LU0405327148.USD","LU2289578879.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407083","title":"恒瑞医药：子公司3款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407083","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660407083?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:02","pubTimestamp":1787216520,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药（600276/01276）发布公告，公司子公司北京盛迪、广东恒瑞及成都盛迪分别收到国家药监局核准签发的《药物临床试验批准通知书》，涉及SHR-8203注射液、SHR-7012注射液及HRS-3095片三款药物，均将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847831616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847831616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU2148510915.USD","LU1064130708.USD","LU0359201612.USD","BK0188","01276","LU2328871848.SGD","BK0183","LU2097828557.USD","LU0405327148.USD","LU1255011170.USD","LU1655091616.SGD","LU1997245094.SGD","LU2580892862.HKD","LU1023057109.AUD","BK0060","LU1820825898.SGD","LU2488822045.USD","LU2097828805.USD","LU1781817850.SGD","BK0012","LU1997245177.USD","LU2097828714.EUR","LU2543165471.USD","BK0028","BK1191","LU1064131003.USD","LU1969619763.USD","LU2495084118.USD","LU1146622755.USD","LU0359201885.HKD","LU2580892789.USD","BK0239","600276","LU1997244956.HKD","LU1580142542.USD","LU2097828631.EUR","LU2289578879.USD","LU0359202008.SGD","LU1328615791.USD","LU2097828474.EUR","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402211","title":"恒瑞医药：HRS-3095片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402211","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402211?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:41","pubTimestamp":1787215260,"startTime":"0","endTime":"0","summary":"南财智讯8月20日电，恒瑞医药公告，HRS-3095片收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展原发免疫性血小板减少症（ITP）和自身免疫性溶血性贫血（AIHA）的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847797826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847797826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327494.USD","MDTX","LU1580142542.USD","BK0060","LU2097828714.EUR","01276","BK0183","LU1023057109.AUD","LU1997245094.SGD","LU2488822045.USD","LU2580892789.USD","LU2328871848.SGD","BK0188","LU1997244956.HKD","LU1064131003.USD","LU2495084118.USD","BK0028","BK0239","PSYK","IBBQ","BK0012","LU1064130708.USD","LU0359201612.USD","LU1146622755.USD","LU1655091616.SGD","LU2289578879.USD","LU1969619763.USD","LU1997245177.USD","LU2543165471.USD","LU1255011170.USD","LU2097828805.USD","LU1820825898.SGD","LU1328615791.USD","LU0359201885.HKD","LU2580892862.HKD","LU0405327148.USD","LU0359202008.SGD","LU2097828631.EUR","BK0196","LU2097828557.USD","BK1191","BMED","600276","LU1781817850.SGD","LU2148510915.USD","IBBJ","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788471656645,"stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.1396},{"period":"3month","weight":-0.0238},{"period":"6month","weight":-0.1694},{"period":"1year","weight":-0.3589},{"period":"ytd","weight":-0.2253}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"539148人(较上一季度增加17.64%)","perCapita":"11831股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}